menu
    • menu
    [{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Slayback Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"Xiromed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Xiromed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xiromed \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ CSL Vifor","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ CSL Vifor"},{"orgOrder":0,"company":"Martini Hospital Groningen","sponsor":"dr. J.M. Munster, gynaecologist, principal investigator","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Phase IV","graph3":"Martini Hospital Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martini Hospital Groningen \/ dr. J.M. Munster, gynaecologist, principal investigator","highestDevelopmentStatusID":"11","companyTruncated":"Martini Hospital Groningen \/ dr. J.M. Munster, gynaecologist, principal investigator"},{"orgOrder":0,"company":"Swiss Federal Institute of Technology","sponsor":"Antistress AG - Burgerstein Vitamine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Swiss Federal Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Federal Institute of Technology \/ Antistress AG - Burgerstein Vitamine","highestDevelopmentStatusID":"1","companyTruncated":"Swiss Federal Institute of Technology \/ Antistress AG - Burgerstein Vitamine"},{"orgOrder":0,"company":"Isabelle Herter-Aeberli","sponsor":"Antistress AG - Burgerstein Vitamine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Isabelle Herter-Aeberli","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isabelle Herter-Aeberli \/ Antistress AG - Burgerstein Vitamine","highestDevelopmentStatusID":"1","companyTruncated":"Isabelle Herter-Aeberli \/ Antistress AG - Burgerstein Vitamine"},{"orgOrder":0,"company":"Isabelle Herter-Aeberli","sponsor":"Antistress AG - Burgerstein Vitamine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Isabelle Herter-Aeberli","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isabelle Herter-Aeberli \/ Antistress AG - Burgerstein Vitamine","highestDevelopmentStatusID":"1","companyTruncated":"Isabelle Herter-Aeberli \/ Antistress AG - Burgerstein Vitamine"},{"orgOrder":0,"company":"Dr. Anil K. Gupta Medicine Professional Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Dr. Anil K. Gupta Medicine Professional Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Fumafer

    Menu

    Fumafer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Anil K. Gupta Medicine Professional Corporation

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dr. Anil K. Gupta Medicine Professional Corporation

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glenmark Pharmaceuticals

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and F...

                            Details : The generic version of Taytulla®1 Capsules, Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, has received approval by the United States Food & Drug Administration.

                            Product Name : Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 29, 2022

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Slayback Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Slayback Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lupin Launches Merzee® Capsules in the United States

                            Details : U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.

                            Product Name : Merzee

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2022

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Martini Hospital Groningen

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Martini Hospital Groningen

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : dr. J.M. Munster, gynaecologist, principal investigator

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy of Intermittent Versus Daily Oral Iron Supplementation in Anaemic Pregnant Women.

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 14, 2022

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : dr. J.M. Munster, gynaecologist, principal investigator

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xiromed

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Xiromed

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®

                            Details : Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.

                            Product Name : Gemmily

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2020

                            Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Isabelle Herter-Aeberli

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Isabelle Herter-Aeberli

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Determination of Iron Absorption Mechanism From Ferrous Fumarate With GOS

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 24, 2019

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Isabelle Herter-Aeberli

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Isabelle Herter-Aeberli

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Determination of a Dose-dependent Effect of GOS on Iron Absorption, and Addition of Vitamin C

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 03, 2018

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Swiss Federal Institute of Technology

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Swiss Federal Institute of Technology

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 30, 2017

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Antistress AG - Burgerstein Vitamine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia

                            Details : Ferrous Fumarate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 18, 2014

                            Lead Product(s) : Ferrous Fumarate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth